Ar­a­digm los­es CEO, CMO and CFO fol­low­ing reg­u­la­to­ry dis­as­ter; Omeros shares go up on pos­i­tive re­sults for blood clot ...

8 years ago
News Briefing

Sil­i­con Val­ley celebs chip in­to $250M round for age-fight­ing start­up Celu­lar­i­ty. Pla­cen­ta-based CAR-Ts on the ...

8 years ago
Startups

Biover­a­tiv inks $100M gene ther­a­py deal with Ox­ford Bio­Med­ica

8 years ago
Pharma
Cell/Gene Tx

Pfiz­er, Mer­ck KGaA say their PD-L1 Baven­cio al­so flunked PhI­II in the all-im­por­tant lung can­cer field

8 years ago
R&D

Af­ter a slap­down on Orkam­bi price, Ver­tex is drop­ping French tri­al sites while warn­ing pa­tients on ac­cess

8 years ago
Pharma

Woe­ful Ax­o­vant starts ax­ing staff, but de­part­ing CEO David Hung gets a $2.6M ex­it pack­age/bonus

8 years ago
R&D
Pharma

Cure­Vac to de­vel­op mR­NA-based flu, malar­ia vac­cines with new Gates Foun­da­tion grants

8 years ago
R&D

FDA's Got­tlieb out­lines new goals in bud­get plan, look­ing to spur drug re­views

8 years ago
Pharma

Bio­gen shares tum­ble af­ter key ex­ec notes a change­up to piv­otal ad­u­canum­ab study due to 'vari­abil­i­ty'

8 years ago
R&D

J&J wins snap ap­proval of apa­lu­tamide, the first drug OK'd for non­metasta­t­ic prostate can­cer

8 years ago
Pharma

Post-con­spir­a­cy claims, Arc­turus los­es an­oth­er ex­ec­u­tive amid board putsch; Gates Foun­da­tion hands $6.5M to No­var­tis ...

8 years ago
News Briefing

Stock slumps for Tel Aviv's Galmed fol­low­ing PhI­Ia NAFLD flop

8 years ago
R&D

Se­nior Mer­ck chemist charged with risk­ing cat­a­stro­phe af­ter pour­ing cyanide in­to Penn­syl­va­nia stormwa­ter drain

8 years ago
Pharma

Switzer­land's Fer­ring Phar­ma to build $32M dis­cov­ery, de­vel­op­ment and man­u­fac­tur­ing cen­ter at HQ

8 years ago
Pharma

What does biotech think about ‘right-to-try'? It might sur­prise you

8 years ago
Pharma

Bris­tol-My­ers las­sos the next big thing in I/O, grabs '214 rights in a record $3.6B deal with Nek­tar

8 years ago
Pharma

Mer­ck just dashed the last re­main­ing hopes for its in­dus­try-lead­ing BACE drug for Alzheimer's

8 years ago
R&D

Tetraphase’s sec­ond PhI­II for its lead an­tibi­ot­ic fails in a re­peat set­back for UTIs

8 years ago
R&D

Kad­mon shares jump on lim­it­ed IPF da­ta; Cel­lec­tis grant­ed two US patents for edit­ing T cells with CRISPR

8 years ago
News Briefing

AI start­up BioX­cel Ther­a­peu­tics shoots for $69M IPO with drugs for Alzheimer's, can­cer

8 years ago
Financing

$100B in NIH-fund­ed re­search played an im­por­tant role in all 210 new drugs ap­proved over 7 years — study

8 years ago
R&D
Discovery

Eli Lil­ly touts PhI­II suc­cess for Taltz as ri­val No­var­tis stays well out front in crowd­ed im­munol­o­gy race

8 years ago
R&D

Charles Riv­er bags a ri­val CRO play­er in $800M MPI Re­search buy­out

8 years ago
Deals
Outsourcing

New year, new tax rates. How did the world’s biggest drug­mak­ers fare?

8 years ago
R&D
First page Previous page 1058105910601061106210631064 Next page Last page
A service from the Financial Times